Dana-Farber and Fitbit partner to test if weight loss can prevent breast cancer recurrence
Dana-Farber Cancer Institute and Fitbit today announced a partnership to support a potentially ground-breaking study that investigates the impact of weight loss on breast cancer recurrence. The Breast Cancer Weight Loss (BWEL) study, sponsored by the National Cancer Institute and the Alliance for Clinical Trials in Oncology, will enroll nearly 3,200 overweight and obese women with early stage breast cancer to test if weight loss can help prevent their disease from returning. The study will begin in August 2016 and enroll women with breast cancer through oncology practices across the Unites States and Canada. Fitbit is donating specific products that will help participants stay motivated and engaged while tracking their weight loss journey and allow their coaches to make sure participants meet their weight loss and fitness goals.
According to the American Cancer Society, approximately 20% of women treated for breast cancer today experience a recurrence of the disease, with most of those women developing metastatic breast cancer. Excess body weight has long been linked to an increased risk of developing breast cancer, and growing evidence suggests that obesity is associated with poor prognosis in women diagnosed with early stage breast cancer. However, despite many reports supporting a relationship between weight and breast cancer prognosis, there have been no studies examining the effect of weight loss upon the risk of breast cancer recurrence.
“The increased risk of cancer recurrence linked to excess body weight threatens to limit our progress in treating breast cancer and preventing women from dying from this disease,” said Jennifer Ligibel, MD, a breast oncologist in the Susan F. Smith Center for Women’s Cancers at Dana-Farber, and lead investigator of the BWEL trial. “If this study shows that losing weight through increasing physical activity and reducing calories improves survival rates in breast cancer, this could lead to weight loss and physical activity becoming a standard part of the treatment for millions of breast cancer patients around the world.”
To help study investigators closely track activity and weight loss among study participants, each participant will receive a Fitbit Charge HRTM fitness tracker that delivers all-day activity tracking and continuous, wrist-based heart rate tracking. Participants will also receive a Fitbit Aria® Wi-Fi Smart Scale that tracks weight, BMI, lean mass and body fat percentage over time and wirelessly syncs to the Fitbit online or mobile dashboard to help users stay on track towards goals. Lastly, participants will also have access to FitStarTM by Fitbit premium software, which offers personalized video-based exercise experiences on mobile devices.
“It will be a challenge to help hundreds of women lose weight without actually ever meeting them face-to-face,” says Ligibel. “Fitbit products will allow coaches to see how participants are doing in terms of meeting their weight, physical activity and caloric goals, and step in when women need extra support to stay on track.”
Participants in the BWEL study will be randomized to a two-year weight loss intervention, plus either a health education program designed to provide information about breast cancer topics, or to a health education program-alone control group. Patients in the weight loss group will work with a health coach over the phone to help them increase their exercise and reduce calories. Fitbit Charge HR and the Aria Wi-Fi scale are being provided to help patients track progress throughout the study and help them to stay motivated to meet their goals. Coaches will receive the participant’s data with their explicit consent to see how they are doing, give encouragement and a little nudge when needed to help participants stay on track.
“We are thrilled to partner with Dana-Farber Cancer Institute on this type of intervention research, helping find a link between key behavioral changes and breast cancer recurrence and potentially helping reduce the terrible burden of cancer for millions of women and their families worldwide,” said Woody Scal, Chief Business Officer, Fitbit. “At Fitbit, we are focused on giving individuals the data, inspiration and guidance they need to help them reach their health and fitness goals. We hear stories every day about how our products help motivate people be more proactive with their health by being more active, eating smarter, sleeping better, and managing their weight – all of which are so important in preventive health.”
This study is being conducted through the Alliance for Clinical Trials in Oncology, a cooperative group within the National Clinical Trials Network (NCTN).
The study is not enrolling participants at this time. We expect it to be activated in August 2016.
You may be eligible if:
Please reach out to your oncologist or medical team to discuss if this trial is a good fit for you and to see if the facility where you received treatment is participating. For more information and updates about the trial visit BWEL Study.
If you are a Dana-Farber patient and you fit the eligibility criteria above, please contact 857-215-2935 or BWELStudy@partners.org.
- You have had a stage II-III breast cancer diagnosis within the past 12 months
- You had surgery for your breast cancer and completed chemotherapy, if applicable
- You are interested in losing weight and have a body mass index (or BMI) greater than 27 kg/m2